A federal judge granted Amarin Corp.'s (Nasdaq: AMRN) request for a summary
judgment in the biopharmaceutical's suit seeking Food and Drug
Administration recognition of a five-year marketing exclusivity for
Vascepa. The stock price climbed 37 cents to close at $2.32.
Judge grants Amarin's request
May 28, 2015 at 17:16 PM EDT
